| Nov 1 |
individual investors who own 55% along with institutions invested in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) saw increase in their holdings value last week
|
| Oct 23 |
Sangamo: Fabry Disease Gene Therapy Moves Forward With Positive FDA Regulatory Development
|
| Oct 23 |
Merck acquires cancer drug startup; Elevidys ex-US sales rise
|
| Oct 22 |
Sangamo stock rallies 37% on FDA update for Fabry disease drug
|
| Oct 22 |
Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025
|
| Oct 21 |
Sangamo Follow-Up: Giro-Vec And STAC-BBB? Check. Isa-Vec... Trifecta Soon?
|
| Sep 21 |
Investors in Sangamo Therapeutics (NASDAQ:SGMO) from three years ago are still down 90%, even after 13% gain this past week
|
| Aug 9 |
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Just Reported And Analysts Have Been Lifting Their Price Targets
|
| Aug 7 |
Q2 2024 Sangamo Therapeutics Inc Earnings Call
|
| Aug 7 |
Genentech and Sangamo to develop neurodegenerative disease therapies
|
